Pulmonary hypertension (PH) is a devastating disease, for which there is no cure. Despite the rarity of the disease, the potential commercial rewards from drugs approved for it are considerable, driven by the premium price that may be charged for PH agents. Commercial interest in PH has increased thanks to recent and significant advances in the understanding of its etiology and pathophysiology and the emergence of new therapies to treat the disease.

Questions Answered in This Report:

  • Macitentan (Actelion’s Opsumit) was the first PH agent to be evaluated in clinical trials for a morbidity/mortality benefit. What do physicians think about the efficacy of this agent in comparison to the other drugs in this class? What impact will it have on the prescribing of bosentan (Actelion’s Tracleer) and ambrisentan (Gilead’s Letairis/GlaxoSmithKline’s Volibris)? What impact will the AMBITION trial and emergence of generics have on the dynamics of the endothelin receptor antagonist (ERA) market?

  • Riociguat (Bayer HealthCare’s Adempas) was recently approved and has launched for the treatment of both pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). What is the impact of the launch of riociguat on the PH market? Which patients will be prescribed riociguat? What do physicians think of this first-in-class agent? Where will it be used in the treatment algorithm for PH? Given that riociguat is the first therapy indicated for the treatment of two WHO groups, what impact will its approval have on the PH market?

  • We forecast that, by 2015, Actelion’s selexipag (Uptravi) will launch in the PAH market. What will be the impact of this launch on medical practice, and what will be the impact on drug sales? What do physicians think of the trial design and likely positioning of this agent in the treatment algorithm?

Scope:

Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.

Primary research: Approximately 20 country-specific interviews with PH thought leaders and experts.

Epidemiology: Prevalence of PH in each of the five WHO groups.

Population segments in market forecast: Each of the five PH WHO groups in each of the major markets we cover.

Emerging therapies: Phase II: 11 drugs; Phase III: 2 drugs. Coverage of 15 select preclinical and Phase I products.

Author(s): Alexandra Hemsley, M.Sc., Eng.D.
Courtney Walls, M.P.H.

Related Reports

Pulmonary Hypertension - Landscape & Forecast - Disease Landscape & Forecast

Pulmonary hypertension (PH) is a devastating disease with high levels of morbidity and mortality and no cure. Despite the disease’s rarity, the pot...

View Details

Hypertension - Unmet Need - Detailed, Expanded Analysis 2020

Primary, or essential, hypertension is defined as persistently elevated blood pressure without any identifiable cause. It is a major risk factor for various cardiovascular diseases (e.g., coronary...

View Details

Hypertension - Current Treatment - Detailed, Expanded Analysis (US)

Primary, or essential, hypertension is defined as persistently elevated blood pressure (BP) without any identifiable cause. It is a major risk factor for various...

View Details

Pulmonary Hypertension - Current Treatment - Detailed, Expanded Analysis (EU5)

Pulmonary hypertension (PH) is a rare and life-threatening disorder marked by considerable morbidity and mortality. Off-label drug use is widespread because drugs have been approved only for the tr...

View Details